Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter "Meiji") announced that the company has concluded an investment agreement wi ...
Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and enhance the global network.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback